PE09532017A1 - CD79b antibodies and methods of use - Google Patents

CD79b antibodies and methods of use

Info

Publication number
PE09532017A1
PE09532017A1 PE2017000955A PE0009552017A PE09532017A1 PE 09532017 A1 PE09532017 A1 PE 09532017A1 PE 2017000955 A PE2017000955 A PE 2017000955A PE 0009552017 A PE0009552017 A PE 0009552017A PE 09532017 A1 PE09532017 A1 PE 09532017A1
Authority
PE
Peru
Prior art keywords
hvr
seq id
amino acid
acid sequence
sequence seq
Prior art date
Application number
PE2017000955A
Other languages
Spanish (es)
Inventor
Liping L Sun
Yvonne Man-Yee Chen
Mark Dennis
Jr Allen J Ebens
Andrew Polson
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201462088487P priority Critical
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE09532017A1 publication Critical patent/PE09532017A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55022708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE09532017(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se refiere a un anticuerpo anti-CD79b que comprende: a) Tres regiones hipervariables de cadena pesada (HVR-H) tales como HVR-H1 que comprende la secuencia de aminoacidos SEC ID NO: 5; It relates to an anti-CD79b antibody comprising: a) Three hypervariable regions heavy chain (HVR-H) HVR-H1 such as comprising the amino acid sequence SEQ ID NO: 5; HVR-H2 que comprende la secuencia de aminoacidos SEC ID NO:8; HVR-H2 comprising the amino acid sequence SEQ ID NO: 8; y HVR-H3 que comprende la secuencia de aminoacidos SEC ID NO: 9; and HVR-H3 comprising the amino acid sequence SEQ ID NO: 9; yb) tres regiones hipervariables de cadena ligera (HVR-L) tales como HVR-L1 que comprende la secuencia de aminoacidos SEC ID NO: 10; b) three hypervariable regions of light chain (HVR-L) such as HVR-L1 comprising the amino acid sequence SEQ ID NO: 10; HVR-L2 que comprende la secuencia de aminoacidos SEC ID NO: 11 y HVR-L3 que comprende la secuencia de aminoacidos SEC ID NO:12. HVRL2 comprising the amino acid sequence SEQ ID NO: 11 and HVR-L3 comprising the amino acid sequence SEQ ID NO: 12. Tambien se refiere a un acido nucleico; It also refers to a nucleic acid; a un vector de expresion; to an expression vector; a una celula huesped; a host cell; a un inmunoconjugado ya una composicion farmaceutica. an immunoconjugate and a pharmaceutical composition. Dicho anticuerpo es util en el tratamiento de trastornos proliferativos tales como el cancer, linfomas, linfoma no hodgkiniano, entre otros Such antibody is useful in the treatment of proliferative disorders such as cancer, lymphomas, non-Hodgkin lymphoma, among others
PE2017000955A 2014-12-05 2015-12-04 CD79b antibodies and methods of use PE09532017A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201462088487P true 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
PE09532017A1 true PE09532017A1 (en) 2017-07-13

Family

ID=55022708

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000955A PE09532017A1 (en) 2014-12-05 2015-12-04 CD79b antibodies and methods of use

Country Status (23)

Country Link
US (2) US9975949B2 (en)
EP (1) EP3227336B1 (en)
JP (1) JP2018505849A (en)
KR (1) KR20170086549A (en)
CN (1) CN107108739A (en)
AR (1) AR102918A1 (en)
AU (1) AU2015358325A1 (en)
BR (1) BR112017011326A2 (en)
CA (1) CA2966362A1 (en)
CL (1) CL2017001408A1 (en)
CO (1) CO2017006740A2 (en)
CR (1) CR20170230A (en)
DK (1) DK3227336T3 (en)
EA (1) EA201790984A1 (en)
IL (1) IL251970D0 (en)
LT (1) LT3227336T (en)
MX (1) MX2017007049A (en)
PE (1) PE09532017A1 (en)
PH (1) PH12017500877A1 (en)
SG (1) SG11201704449VA (en)
SI (1) SI3227336T1 (en)
TW (1) TW201636366A (en)
WO (1) WO2016090210A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6449295B2 (en) 2013-12-17 2019-01-09 ジェネンテック, インコーポレイテッド Anti-CD3 antibodies and methods of use
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
JP2018527887A (en) 2015-06-16 2018-09-27 ジェネンテック, インコーポレイテッド Humanized affinity matured antibodies against FcRH5 and methods of use

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A (en) 1988-04-28 1989-10-29 Univ Leland Stanford Junior I Reseptordeterminanter anti-t-celler Foer Treatment of autoimmune disease.
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
ES2062519T5 (en) 1989-03-21 2003-07-16 Immune Response Corp Inc Vaccines and methods against originated from pathogenic responses by specific populations of T cells diseases.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
KR100216097B1 (en) 1989-07-19 1999-08-16 크리스토퍼 제이. 마골린 T cell receptor peptides as therapeutics for autoimmune and malignant disease
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AT164395T (en) 1990-12-03 1998-04-15 Genentech Inc A method for enrichment of protein variants with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (en) 1997-06-24 2005-12-01 Genentech, Inc. Procedure and compositions of galactosilated glicoproteins.
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (en) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
WO2000061739A1 (en) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Method for controlling the activity of immunologically functional molecule
DE60022369T2 (en) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Process for regulating the transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP4668498B2 (en) 1999-10-19 2011-04-13 協和発酵キリン株式会社 Method for producing polypeptide
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531821A (en) 1999-12-29 2003-10-28 イムノージェン インコーポレーテッド The use of cytotoxic agents as well as therapeutic thereof comprising a modified doxorubicin and daunorubicin
ES2528794T3 (en) 2000-04-11 2015-02-12 Genentech, Inc. multivalent antibodies and uses thereof
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EA013224B1 (en) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Cells producing antibody composition
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
RU2321630C2 (en) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Glycosylated antibodies (variants) possessing enhanced antibody-dependent cellular cytotoxicity
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
EA200401325A1 (en) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Cells with modified genom
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
AT503829T (en) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Cell with reduced or deleted activity of a protein involved in gdp fucoset transport
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
WO2003102157A2 (en) 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RU2326127C2 (en) 2002-12-16 2008-06-10 Джинентех, Инк. Versions of immunoglobulins and its application
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
WO2005035778A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE
EA015009B1 (en) 2003-11-05 2011-04-29 Гликарт Биотехнологи Аг Antigen-binding molecules have an increased affinity for binding to Fc-receptors and effector functions
ES2557389T3 (en) 2003-11-06 2016-01-25 Seattle Genetics, Inc. Monomethylvaline compounds conjugated with antibodies
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (en) 2004-04-13 2013-04-16 Hoffmann La Roche Anti-p-selectin antibodies
KR20120064120A (en) 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
WO2006114115A1 (en) 2005-04-26 2006-11-02 Trion Pharma Gmbh Combination of antibodies and glucocorticoids for treating cancer
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (en) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッドGenentech,Inc. Binding polypeptide with optimized scaffold
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20100150918A1 (en) 2007-04-03 2010-06-17 Micromet Ag Cross-species-specific binding domain
CN101675077B (en) 2007-04-03 2013-09-04 安进研发(慕尼黑)股份有限公司 Cross-species-specific bispecific binders
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司;群创光电股份有限公司 Liquid crystal panel drive device and its drive method
MX2010008437A (en) * 2008-01-31 2010-11-25 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use.
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CA2693255A1 (en) 2007-07-16 2009-01-22 Yvonne Chen Anti-cd79b antibodies and immunoconjugates and methods of use
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
JP5367587B2 (en) * 2008-02-08 2013-12-11 三洋電機株式会社 Solar cell module and solar cell
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP3228315A1 (en) 2010-11-10 2017-10-11 Amgen Research (Munich) GmbH Prevention of adverse effects caused by cd3 specific binding domains
CA2836857A1 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
DK2748201T3 (en) 2011-08-23 2018-02-12 Roche Glycart Ag Bispecific t-cell activating antigin binding molecules
WO2014011519A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
CA2874856A1 (en) * 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
CN104379169A (en) 2012-08-14 2015-02-25 Ibc药品公司 T-cell redirecting bispecific antibodies for treatment of disease
AR092612A1 (en) 2012-09-21 2015-04-29 Regeneron Pharma Anti-CD3 antibodies, bispecific binding molecules that bind antigen CD3 and CD20, and uses thereof
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EA201891502A1 (en) 2013-02-26 2018-12-28 Роше Гликарт Аг Bispecific antigensive-bonding molecules activating t-cells
US20140302064A1 (en) 2013-03-12 2014-10-09 Xencor, Inc. Optimized anti-cd3 variable regions
EP2968552A4 (en) 2013-03-14 2016-09-14 California Inst Biomedical Res Targeting agent antibody conjugates and uses thereof
WO2014191113A1 (en) 2013-05-28 2014-12-04 Numab Ag Novel antibodies
SG10201808519VA (en) 2013-12-17 2018-10-30 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
JP6449295B2 (en) 2013-12-17 2019-01-09 ジェネンテック, インコーポレイテッド Anti-CD3 antibodies and methods of use
PL3177643T3 (en) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
US20160368994A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
JP2018527887A (en) 2015-06-16 2018-09-27 ジェネンテック, インコーポレイテッド Humanized affinity matured antibodies against FcRH5 and methods of use

Also Published As

Publication number Publication date
BR112017011326A2 (en) 2018-07-31
DK3227336T3 (en) 2019-09-16
AR102918A1 (en) 2017-04-05
US9975949B2 (en) 2018-05-22
KR20170086549A (en) 2017-07-26
CO2017006740A2 (en) 2018-01-05
IL251970D0 (en) 2017-06-29
EP3227336B1 (en) 2019-07-03
SG11201704449VA (en) 2017-06-29
CN107108739A (en) 2017-08-29
AU2015358325A1 (en) 2017-05-25
MX2017007049A (en) 2018-05-02
EA201790984A1 (en) 2018-05-31
EP3227336A1 (en) 2017-10-11
CA2966362A1 (en) 2016-06-09
SI3227336T1 (en) 2019-10-30
JP2018505849A (en) 2018-03-01
US20160159906A1 (en) 2016-06-09
CL2017001408A1 (en) 2018-01-05
US20180327492A1 (en) 2018-11-15
PH12017500877A1 (en) 2017-11-06
CR20170230A (en) 2017-11-07
WO2016090210A1 (en) 2016-06-09
LT3227336T (en) 2019-09-25
TW201636366A (en) 2016-10-16

Similar Documents

Publication Publication Date Title
CR20170059A (en) Anti-LAG3 and fragments of antigen binding
BR112016022798A2 (en) cancer treatment using anti-cd19 chimeric antigen receptor
BR112016020112A2 (en) multispecific antibodies, method for preparing a multispecific antibody, nucleic acid, expression vector, and pharmaceutical composition
AR095432A1 (en) Antigen binding proteins
AR088694A1 (en) Cytotoxic peptide conjugates and antibody-drug thereof
DOP2014000007A (en) Antigen-binding proteins of TNF-alpha with increased FcRn binding
WO2016011210A3 (en) Engineered cells for adoptive cell therapy
PE07792017A1 (en) Antibodies reactive with B7-h3, immunologically active fragments thereof and uses thereof
PE12172016A1 (en) Anti-CD3 antibodies and methods of use
JP2014526898A5 (en)
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
UA119167C2 (en) Bispecific antibodies that bind to cd38 and cd3
PE11472014A1 (en) PCSK9 antibodies and uses thereof
ES2687282T3 (en) ANTI-CD134 (OX40) humanized antibodies and their uses
EA201391170A1 (en) Therapeutic means based on yeast for the treatment of chronic hepatitis b
MX2017001011A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor.
BR112017003108A2 (en) antibody or antigen binding fragment thereof, isolated polypeptide, isolated nucleic acid, expression vector, host cell, composition, methods for producing an antibody or antigen binding fragment for treating cancer and an infection or infectious disease for detecting the presence of a tigit peptide or fragment thereof and for enhancing the activity of an immune cell and the antitumor activity of an anti-tigit antibody, vaccine, and use of an antibody or antigen binding fragment
EA201400875A1 (en) Antibodies to cd47 and methods of their application
EA201400625A1 (en) Antibodies against pd-l1 and their application
MY160499A (en) Anti-cd38 antibodies
EA201490288A1 (en) Human binding molecules, ableable to neutralize influenza a viruses of philogenetic group 1 and phylogenetic group 2 and influenza viruses
PE13222018A1 (en) Anti-PD1 and their methods of use
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
NZ631405A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
BR112017021500A2 (en) cd20 therapies, cd22 therapies, and combination therapies with a cell expressing (car) cd19 chimeric antigen receptor